Lupin Limited has informed the Exchange regarding a press release dated Jun 30, 2021, titled "Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine andTenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR.".
Lupin Limited has informed the Exchange regarding a press release dated Jun 30, 2021, titled "Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine andTenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR.".